TY - JOUR
T1 - Enzymatic enhancement of cell mediated cytotoxicity and antibody dependent cell cytotoxicity
AU - Kedar, E.
AU - Ortiz De Landazuri, M.
AU - Fahey, J. L.
PY - 1974
Y1 - 1974
N2 - The effects of papain, trypsin, pronase, neuraminidase, and phospholipase C on in vitro cell mediated cytotoxicity (CMC) and antibody-dependent cell cytotoxicity (ADCC) were studied in a syngeneic tumor system. Proteolytic enzyme treatment of lymphoid (effector) cells at low concentrations (<0.1 mg/ml) and for short times (less than 30 min) produced a 2- to 6-fold increase in CMC and ADCC. Neuraminidase also augmented both CMC and ADCC, whereas phospholipase C had no effect. The specificity of the cytotoxicity (CMC) amplification following enzymatic treatment was indicated by observations that: the activated immune cells were not cytotoxic to unrelated tumor cells, and normal cells were not activated. The enzymatically induced potentiation was observed only with organs which already had demonstrable cytotoxic activity. Kinetic studies indicated that the enzymatic treatment may produce a quantitative as well as a qualitative change in the lymphoid cell population. Enzymatic treatment of lymphoid cells may be a valuable means of increasing the sensitivity of in vitro assays for cell-mediated immunity. Pretreatment of lymphoid cells with high enzyme concentrations (over 1 mg/ml) or for prolonged periods of time (over 1 hr) did not reduce ADCC, but strongly suppressed CMC. This difference in response to proteolytic enzymes emphasizes chemical differences in the membrane components responsible for CMC vs ADCC.
AB - The effects of papain, trypsin, pronase, neuraminidase, and phospholipase C on in vitro cell mediated cytotoxicity (CMC) and antibody-dependent cell cytotoxicity (ADCC) were studied in a syngeneic tumor system. Proteolytic enzyme treatment of lymphoid (effector) cells at low concentrations (<0.1 mg/ml) and for short times (less than 30 min) produced a 2- to 6-fold increase in CMC and ADCC. Neuraminidase also augmented both CMC and ADCC, whereas phospholipase C had no effect. The specificity of the cytotoxicity (CMC) amplification following enzymatic treatment was indicated by observations that: the activated immune cells were not cytotoxic to unrelated tumor cells, and normal cells were not activated. The enzymatically induced potentiation was observed only with organs which already had demonstrable cytotoxic activity. Kinetic studies indicated that the enzymatic treatment may produce a quantitative as well as a qualitative change in the lymphoid cell population. Enzymatic treatment of lymphoid cells may be a valuable means of increasing the sensitivity of in vitro assays for cell-mediated immunity. Pretreatment of lymphoid cells with high enzyme concentrations (over 1 mg/ml) or for prolonged periods of time (over 1 hr) did not reduce ADCC, but strongly suppressed CMC. This difference in response to proteolytic enzymes emphasizes chemical differences in the membrane components responsible for CMC vs ADCC.
UR - http://www.scopus.com/inward/record.url?scp=0015964159&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 4812174
AN - SCOPUS:0015964159
SN - 0022-1767
VL - 112
SP - 26
EP - 36
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -